Volume 24, Number 3—March 2018
Research
Acquired Resistance to Antituberculosis Drugs in England, Wales, and Northern Ireland, 2000–2015
Miranda G. Loutet
, Jennifer A. Davidson, Tim Brown, Martin Dedicoat, H. Lucy Thomas, and Maeve K. Lalor
, Jennifer A. Davidson, Tim Brown, Martin Dedicoat, H. Lucy Thomas, and Maeve K. Lalor
Table 4
Number and proportion of TB cases, by time between treatment initiation and drug resistance acquisition and by acquired drug resistance categories, England, Wales, and Northern Ireland, 2000–2015*
| Time between treatment start and acquired resistance |
Acquired drug resistance category |
|||
| No MDR TB before or after acquiring resistance, no. (%) |
Acquired resistance and MDR TB developed later, no. (%) |
Initial MDR TB with additional resistance acquired later, no. (%) |
Total with acquired drug resistance, no. (%) |
|
| <1 mo | 20 (36.4) | 2 (5.1) | 5 (11.9) | 27 (19.9) |
| 2 mo | 10 (18.2) | 0 | 13 (31.0) | 23 (16.9) |
| 3 mo | 8 (14.5) | 3 (7.7) | 4 (9.5) | 15 (11.0) |
| 4–6 mo | 6 (10.9) | 9 (23.1) | 10 (23.8) | 25 (18.4) |
| 7–9 mo | 4 (7.3) | 8 (20.5) | 5 (11.9) | 17 (12.5) |
| 10 mo–1 y | 4 (7.3) | 7 (18.0) | 1 (2.4) | 12 (8.8) |
| >1 y |
3 (5.5) |
10 (25.6) |
4 (9.5) |
17 (12.5) |
| Total | 55 (100) | 39 (100) | 42 (100) | 136 (100) |
*MDR, multidrug-resistant; TB, tuberculosis.
Page created: February 15, 2018
Page updated: February 15, 2018
Page reviewed: February 15, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.